Intriguingly, we showed that antibodies directed against D1, D2, and D3 domains are all capable of blocking LAG-3 dimer formation and MHCII and FGL-1 ligand binding, suggesting a potential allosteric model of LAG-3 function tightly regulated by dimerization. Furthermore, our work reveals unique epitopes, in addition to D1, that can be targeted for immunotherapy of cancer and other human diseases.
2 months ago
Journal • IO biomarker
|
LAG3 (Lymphocyte Activating 3) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • FGL1 (Fibrinogen Like 1)